TY - JOUR
T1 - Evaluating pathogenicity of variants of unknown significance in APP, PSEN1, and PSEN2
AU - Marsh, Jacob A.
AU - Huang, Guangming
AU - Bowling, Kevin
AU - Renton, Alan E.
AU - Ziegemeier, Ellen
AU - Ball, Torri
AU - Pottier, Cyril
AU - Cruchaga, Carlos
AU - Day, Gregory
AU - Bateman, Randall
AU - Llibre-Guerra, Jorge J.
AU - McDade, Eric
AU - Karch, Celeste M.
N1 - Publisher Copyright:
© 2025 The Author(s)
PY - 2025
Y1 - 2025
N2 - Autosomal dominant Alzheimer's disease (ADAD) is driven by rare variants in APP, PSEN1, and PSEN2. Although more than 200 pathogenic variants in these genes are known to cause ADAD, other variants are benign, may act as risk factors, or may even reduce Alzheimer's disease risk (e.g. protective). Classifying novel variants in APP, PSEN1, or PSEN2 as pathogenic, risk, benign, or protective is a critical step in evaluating disease risk profiles which further impacts eligibility for clinical trials focused on the ADAD population. Here, we classify 53 novel variants in APP, PSEN1, and PSEN2 based on bioinformatic data and cell-based assays. We identified 6 benign variants, 2 risk variants, and 32 likely pathogenic variants. Thirteen variants were associated with reduced Aβ levels in cell-based assays, consistent with a potential protective effect. Together, this study highlights the complexities associated with classification of rare variants in ADAD genes.
AB - Autosomal dominant Alzheimer's disease (ADAD) is driven by rare variants in APP, PSEN1, and PSEN2. Although more than 200 pathogenic variants in these genes are known to cause ADAD, other variants are benign, may act as risk factors, or may even reduce Alzheimer's disease risk (e.g. protective). Classifying novel variants in APP, PSEN1, or PSEN2 as pathogenic, risk, benign, or protective is a critical step in evaluating disease risk profiles which further impacts eligibility for clinical trials focused on the ADAD population. Here, we classify 53 novel variants in APP, PSEN1, and PSEN2 based on bioinformatic data and cell-based assays. We identified 6 benign variants, 2 risk variants, and 32 likely pathogenic variants. Thirteen variants were associated with reduced Aβ levels in cell-based assays, consistent with a potential protective effect. Together, this study highlights the complexities associated with classification of rare variants in ADAD genes.
KW - Autosomal dominant Alzheimer's disease
KW - Cell-based assay
KW - Pathogenicity
KW - Variants of unknown significance
UR - http://www.scopus.com/inward/record.url?scp=85216251653&partnerID=8YFLogxK
U2 - 10.1016/j.neurot.2025.e00527
DO - 10.1016/j.neurot.2025.e00527
M3 - Review article
C2 - 39875235
AN - SCOPUS:85216251653
SN - 1933-7213
JO - Neurotherapeutics
JF - Neurotherapeutics
M1 - e00527
ER -